文献速递癫痫神经重症与神经感染

左乙拉西坦用于创伤性脑损伤后癫痫预防:51,000例严重程度分层队列研究

Levetiracetam for Seizure Prophylaxis after Traumatic Brain Injury: A Severity-Stratified Cohort Study of 51,000 Patients.
PubMed 文献 · Ann Neurol · 2026-06-05

该回顾性队列研究基于TriNetX网络纳入51,263例首次TBI成人患者,评估预防性左乙拉西坦预防癫痫的有效性与不良反应。结果显示左乙拉西坦仅减少重度TBI的早期癫痫(HR=0.55),对轻度TBI早期癫痫及两类TBI的晚期癫痫均无效,且伴有记忆受损等不良反应。

要点

  • 左乙拉西坦仅降低重度TBI(GCS 3-8)的早期癫痫风险(HR=0.55)。
  • 对轻度TBI早期癫痫及轻/重度TBI的晚期癫痫均无预防作用。
  • 鉴于不良反应负担,常规预防应限于重度TBI或高风险患者。

核心结论

  • 预防性左乙拉西坦仅减少重度TBI的早期癫痫,不提供长期保护。
  • 鉴于不良反应负担,常规预防应限于重度TBI或高风险患者。
  • 研究结果支持重新评估当前基于旧抗癫痫药物的癫痫预防指南。

研究设计与样本

  • 纳入≥18岁首次TBI且记录GCS评分的成人,排除既往癫痫、伤当日抽搐或既往左乙拉西坦暴露者。
  • 队列n=51,263,分为轻度(GCS 13-15;n=33,625)和重度(GCS 3-8;n=10,805)TBI。
  • 采用Cox比例风险模型评估早期(<7天)和晚期(<1年)癫痫风险,校正已知预测因素。
  • 不良反应评估长达5年。

主要发现

  • 左乙拉西坦用于14,630例患者(30%)。
  • 校正后,左乙拉西坦减少重度TBI早期癫痫(HR=0.55,95%CI=0.31-0.97,p=0.04),轻度TBI无减少(HR=0.85,95%CI=0.45-1.61,p=0.61)。
  • 左乙拉西坦未减少轻度TBI晚期癫痫(HR=1.00,95%CI=0.79-1.15,p=0.997)或重度TBI晚期癫痫(HR=0.90,95%CI=0.68-1.19,p=0.45)。
  • 年龄较大、脑水肿和硬膜下出血是一致危险因素。
  • 不良结局包括记忆和意识受损、代谢紊乱及精神症状。

关键数值与推荐

  • 重度TBI早期癫痫:HR=0.55,95%CI=0.31-0.97,p=0.04。
  • 轻度TBI早期癫痫:HR=0.85,95%CI=0.45-1.61,p=0.61。
  • 轻度TBI晚期癫痫:HR=1.00,95%CI=0.79-1.15,p=0.997。
  • 重度TBI晚期癫痫:HR=0.90,95%CI=0.68-1.19,p=0.45。

临床怎么用

  • 对重度TBI(GCS 3-8)患者可考虑短期左乙拉西坦预防早期癫痫。
  • 轻度TBI患者不推荐常规使用左乙拉西坦预防癫痫。
  • 用药期间需监测记忆受损、代谢紊乱及精神症状等不良反应。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 研究基于TriNetX数据库,结果外推需谨慎。
  • 未报告左乙拉西坦的具体剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to evaluate the effectiveness and adverse effect profile of prophylactic levetiracetam in preventing epilepsy after traumatic brain injury (TBI). METHODS: This retrospective cohort study used the TriNetX Research Network, encompassing >150 million patients. Adults (≥18 years) with a first TBI and Glasgow Coma Scale (GCS) score recorded were included. Patients with pre-existing epilepsy, seizures on the day of injury, or prior levetiracetam exposure were excluded. The cohort (n = 51,263) was stratified into mild (GCS 13-15; n = 33,625) and severe (GCS 3-8; n = 10,805) TBI. The risk of early (<7 days) and late (<1 year) epilepsy was assessed using Cox proportional hazards models adjusted for known predictors. Adverse events were evaluated for up to 5 years. RESULTS: Levetiracetam was administered to 14,630 patients (30%). After adjustment, levetiracetam reduced early epilepsy in severe TBI (hazard ratio [HR] = 0.55, 95% confidence interval [CI] = 0.31-0.97, p = 0.04) but not in mild TBI (HR = 0.85, 95% CI = 0.45-1.61, p = 0.61). Levetiracetam did not reduce late epilepsy in either mild (HR = 1.00, 95% CI = 0.79-1.15, p = 0.997) or severe (HR = 0.90, 95% CI = 0.68-1.19, p = 0.45) TBI. Older age, cerebral edema, and subdural hemorrhage were consistent risk factors. Adverse outcomes included impaired memory and awareness, metabolic disorders, and psychiatric symptoms. INTERPRETATION: Levetiracetam prophylaxis reduced early epilepsy only in severe TBI and conferred no long-term protection. Given its adverse effect burden, routine prophylaxis should be limited to severe TBI or high-risk patients. These findings support re-evaluation of current seizure prophylaxis guidelines, which are based on older antiseizure medications and predate large-scale real-world data. ANN NEUROL 2026;100:416-425.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Thorman IB, Sacknovitz A, Li AG, et al. Levetiracetam for Seizure Prophylaxis after Traumatic Brain Injury: A Severity-Stratified Cohort Study of 51,000 Patients. Ann Neurol. 2026. PMID: 42249536. doi:10.1002/ana.78273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。